Last week, the Intrommune team presented in support of its Oral Mucosal Immunotherapy (OMIT) at Citizens JMP Life Science Conference and the BioNJ BioPartnering Conference, and CEO Michael Nelson will represent Intrommune as a panelist at this year’s Annual Food Allergy Fund Summit.
Intrommune today announced the appointment of Dr. Jonathan Rich to its board of directors and Hem Pandya as Executive Chairman of the board of directors.
New study is the first to evaluate Oral Mucosal Immunotherapy (OMIT) for the treatment of food allergy.
New study is the first to evaluate Oral Mucosal Immunotherapy (OMIT) for the treatment of food allergy.
The combination of these two approaches is expected to result in the rapid and long-term relief of allergic symptoms resulting from peanut exposure and would be a game changer for patients suffering with this potentially life-threatening allergy.
Study met all primary and secondary safety endpoints, demonstrating INT301 was well-tolerated. A small subset analysis provided indications of efficacy. Full data set to be reported next year, followed by initiation of the Phase 2 clinical trial in a pediatric population.